1315330-11-0

1315330-11-0 structure

Name: B-Raf inhibitor
Chemical Name: N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[(6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]benzamide
CAS Number: 1315330-11-0
Molecular Formula: C₂₉H₃₁F₃N₆O₂
Molecular Weight: 552.59100
Catalog: Signaling Pathways MAPK/ERK Pathway MAP3K
Create Date: 2016-03-12 01:16:28
Modify Date: 2024-01-08 00:10:14
TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively.

Name	N-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[(6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]benzamide
Synonyms	N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methyl-3-((6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)benzamide B-Raf inhibitor\| CS-1099 N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[(6-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]benzamide B-Raf inhibitor

Description	TAK1/MAP4K2 inhibitor 1 is a potent dual TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2) inhibitor, with IC50s of 41.1 nM and 18.2 nM, respectively.
Related Catalog	Signaling Pathways >> MAPK/ERK Pathway >> MAP3K Signaling Pathways >> MAPK/ERK Pathway >> MAP4K Research Areas >> Cancer
Target	TAK1:41.1 nM (IC50) MAP4K2:18.2 nM (IC50)
In Vivo	TAK1/MAP4K2 inhibitor 1 has moderate terminal elimination half-life (t1/2=2.94 h for mice (1 mg/kg, iv))[1].
References	[1]. Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96.